Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New feature:   Automatically detect candlestick patterns on any chart

Read How
Market News Market Pulse Stocks News ETF News Crypto News

InflaRx N.V.

Contributing Author

Recent Articles by InflaRx N.V.

Aug-20
InflaRx Announces Participation in September Investor Conferences IFRX GlobeNewswire
Aug-06
InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones IFRX GlobeNewswire
Jul-30
InflaRx to Report Second Quarter 2026 Results on August 6, 2026 IFRX GlobeNewswire
Jun-30
InflaRx Assessing Feasibility of Broadened Strategy for ANCA-Associated Vasculitis in Europe Following EMA Recommendation on Tavneos IFRX GlobeNewswire
May-08
InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares IFRX GlobeNewswire
May-06
InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares IFRX +26.90% GlobeNewswire
May-06
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases IFRX +26.90% GlobeNewswire
May-04
InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes IFRX GlobeNewswire
May-01
InflaRx to Report First Quarter 2026 Results on May 7, 2026 IFRX GlobeNewswire
Apr-28
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement IFRX GlobeNewswire
Apr-09
InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor IFRX +8.42% GlobeNewswire
Mar-31
InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium IFRX +7.54% GlobeNewswire
Mar-30
InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting IFRX -8.79% GlobeNewswire
Mar-19
InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones IFRX GlobeNewswire
Mar-18
InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting IFRX GlobeNewswire
Mar-13
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement IFRX GlobeNewswire
Mar-12
InflaRx to Report Full Year 2025 Results on March 19, 2026 IFRX GlobeNewswire
Feb-26
InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference IFRX GlobeNewswire
Jan-29
InflaRx Announces Participation in February Investor Conferences IFRX GlobeNewswire
Jan-08
InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation IFRX -9.17% GlobeNewswire
Dec-30
InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum IFRX GlobeNewswire
Dec-11
InflaRx Announces International Nonproprietary Name of "Izicopan" for INF904 IFRX GlobeNewswire
Nov-10
InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU) IFRX +28.46% GlobeNewswire
Nov-07
InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria IFRX GlobeNewswire
Oct-21
InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference IFRX GlobeNewswire
Sep-12
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement IFRX -14.29% GlobeNewswire
Aug-21
InflaRx Announces Participation in September Investor Conferences IFRX GlobeNewswire
Aug-07
InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update IFRX GlobeNewswire
Jul-31
InflaRx to Report Second Quarter 2025 Results on August 7, 2025 IFRX GlobeNewswire
Jul-11
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement IFRX GlobeNewswire
May-28
InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum IFRX -59.86% GlobeNewswire
May-22
InflaRx to Participate in Upcoming Investor Conferences IFRX +7.69% GlobeNewswire
May-07
InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update IFRX -7.45% GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)